Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
---|---|---|---|---|---|---|---|---|
2024-03-12 | Jasper Therapeutics, Inc. | Mahal Jeetinder S...
(Chief Operating Officer) |
S | Voting Common Stock | D | 900 | $26.44 - $26.44 | $23,792 |
2024-03-12 | Jasper Therapeutics, Inc. | Mahal Jeetinder S...
(Chief Operating Officer) |
M | Voting Common Stock | A | 900 | $7.10 - $7.10 | $6,390 |
2024-02-08 | Jasper Therapeutics, Inc. | Abingworth Bioven...
(AtLeastTenPercentOwner) |
P | Voting Common Stock | A | 190000 | $12.95 - $12.95 | $2,460,500 |
2024-02-08 | Jasper Therapeutics, Inc. | Morgan Adam
(AtLeastTenPercentOwner) |
P | Common Stock, par value $0.0001 per share | A | 350000 | $12.95 - $12.95 | $4,532,500 |
2023-11-21 | Jasper Therapeutics, Inc. | WIGGANS THOMAS G
(Director) |
P | Voting Common Stock | A | 10000 | $0.64 - $0.64 | $6,383 |
2023-11-16 | Jasper Therapeutics, Inc. | WIGGANS THOMAS G
(Director) |
P | Voting Common Stock | A | 30000 | $0.60 - $0.63 | $18,240 |
A | Grant, award or other acquisition |
C | Conversion of Derivative or Security |
D | Disposition to the issuer of issuer equity securities |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability |
G | Bona fide Gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary Transaction |
J | Other acquisition or disposition |
K | Transaction in equity swap or instrument with similar characteristics |
L | Small Acquisition |
M | Exercise or conversion of derivative security |
O | Exercise of out-of-the-money derivative security |
P | Open Market Purchase |
S | Open Market Sale |
U | Disposition pursuant to a tender of shares in a change of control transaction |
V | Transaction Voluntarily Reported |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |